Cost–effectiveness of HMG-CoA reductase inhibitors in the treatment of dyslipidemia and prevention of CHD

References Papers of special note have been highlighted as:• of interest•• of considerable interest

• American Heart Association. Heart and Stroke Statistics – 2005 Update. American Heart Association, TX, USA (2005).
   Google Scholar
• Stamler J, Wentworth D, Neaton JD et al. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of multiple risk factor intervention trial (MRFIT). JAMA 256, 2823–2828 (1986).
   PubMed Web of Science ®Google Scholar
• Castelli WP, Anderson KW, Wilson PW et al. Lipids and risk of coronary heart disease: The Framingham Study. Ann. Epidemiol. 2, 23–28 (1992).
   PubMedGoogle Scholar
• Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251, 351–364 (1984).
   PubMedGoogle Scholar
• Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 257, 2176–2180 (1987).
   PubMed Web of Science ®Google Scholar
• Berenson GS, Srinivasam SR, Bao WP III, Tracy RE, Wattingney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med. 338, 1650–1656 (1998).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel: Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Arch. Intern. Med. 148, 36–69 (1988).
   PubMed Web of Science ®Google Scholar
• Talbert RL. New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel III. Am. J. Manag. Care 8(Suppl.), 301–307 (2002).
   Google Scholar
• Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 269, 3015–3023 (1993).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CNB et al., for the Co-ordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation 110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Greenland P, Grundy SM. Prevention conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. Circulation 101, 111–116 (2000).
   PubMedGoogle Scholar
• Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 106, 388–391 (2002).
   PubMed Web of Science ®Google Scholar
• Mosca L, Appel LJ, Benjamin EJ et al. Evidence based guidelines for cardiovascular disease prevention in women. Circulation 109, 672–693 (2004).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D. The Veterans Affairs High-Density Lipoprotein Intervention Trial: baseline characteristics of normocholesterolemic men with coronary artery disease and low levels of high-density lipoprotein cholesterol. Am. J. Cardiol. 78, 572–575 (1996).
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999).
   PubMed Web of Science ®Google Scholar
• Khreiss T, J-zsef L, Potempa LA, Lipe JC. Conformational rearrangement in C-reactive protein is required for pro-inflammatory actions in human endothelial cells. Circulation 109, 2016–2022 (2004).
   PubMed Web of Science ®Google Scholar
• Knopp RH. Drug treatment of lipid disorders. N. Engl. J. Med. 341, 498–511 (1999).
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering of 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383–1389 (1994).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl J. Med. 333, 1301–1307 (1995).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med. 335, 1001–1009 (1996).
   PubMed Web of Science ®Google Scholar
• The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N. Engl. J. Med. 336, 153–162 (1997).
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of the AFCAPS/TexCAPS. JAMA 279, 1615–1622 (1998).
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med. 339, 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Plehn JF, Davis BR, Sacks FM et al. Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol And Recurrent Events (CARE) study. Circulation 99, 216–223 (1999).
   PubMed Web of Science ®Google Scholar
• Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 97, 946–952 (1995).
   Google Scholar
• Cowie MR. Statins: where are we now? Hosp. Med. 61, 789–792 (2000).
   PubMedGoogle Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med. 160, 459–467 (2000).
   PubMed Web of Science ®Google Scholar
• Latts LM. Assessing the results: Phase 1 hyperlipidemia outcomes in 27 health plans. Am. J. Med. 110(Suppl.), 605–610 (2001).
   PubMedGoogle Scholar
• Schultz JS, O’Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am. J. Manag. Care 11, 306–312 (2005).
   PubMed Web of Science ®Google Scholar
• Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 15, 47–74 (1999).
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Cziraky MJ. Economics of lipid lowering: focus on statins. P&T 26, 208–216 (2001).
   Google Scholar
• Zowall H, Grover SA. Costs of dyslipidemia. Exp. Rev. Pharmacoeconomics Outcomes Res. 3, 273–281 (2003).
   PubMedGoogle Scholar
• Pasternak RC, Smith SC, Bairey-Merz N et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106, 1024–1028 (2002).
   PubMed Web of Science ®Google Scholar
• Worz CR, Bottoroff M. Treating dyslipidemic patients with lipid-modifying and combination therapies. Pharmacotherapy 23, 625–637 (2003).
   PubMedGoogle Scholar
• Bazalo GR. Managed care trends in statin usage. Manag. Care 10, 48–59 (2001).
   PubMedGoogle Scholar
• Robers WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am. J. Cardiol. 82, 106–107 (1997).
   Google Scholar
• Jacobson TA, Schein JR, Williamson A, Ballantyne CM. Maximizing the cost–effectiveness of lipid lowering therapy. Arch. Intern. Med. 158, 1977–1989 (1998).
   PubMed Web of Science ®Google Scholar
• Edwards JE, Moore RA. Statins in hypercholesterolaemia: a dose-specific meta-analysis of lipid changes in randomised, double-blind trials. Open Access Article © 2003 Edwards and Moore; licensee BioMed Central Ltd. BMC Fam. Pract. 4, 18 (2003).
   PubMedGoogle Scholar
• Yusuf S, Hawken S, Ôunpuu S, Dans T et al., for the INTERHEART Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case control study. Lancet 364, 937–952 (2004).
   PubMed Web of Science ®Google Scholar
• Watkins LO. Epidemiology and burden of cardiovascular disease. Clin. Cardiol. 27(Suppl.), 2–6 (2004).
   Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering after acute coronary syndromes. N. Engl J. Med. 350, 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Pitt B. Low-density lipoprotein cholesterol in patients with stable coronary heart disease – is it time to shift our goals? N. Engl. J. Med. 325, 1483–1484 (2005).
   Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al., for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med. 352, 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project Research Group: long-term benefit with niacin. J. Am. Coll. Cardiol. 8, 1245–1255 (1986).
   PubMed Web of Science ®Google Scholar
• Pitt B, Mancini J, Ellis SG et al. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-I) : reduction in Atherosclerosis progression and clinical events. J. Am. Coll. Cardiol. 26, 1133–1139 (1995).
   PubMed Web of Science ®Google Scholar
• Crouse JB, Byington RP, Bond MG et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am. J. Cardiol. 75, 455–459 (1995).
   PubMed Web of Science ®Google Scholar
• Frick MH, Elo O, Haapa K et al. Helsinki Heart Study: primary prevention with gemfibrozil in middle-aged men with dyslipidemia. N. Engl. J. Med. 317, 1237–1245 (1987).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. PROspective Study of Pravastatin in the Elderly at Risk. Lancet 360, 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Co-ordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid-Lowering Treatment To Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998–3007 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al., on behalf of the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361, 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• La Rosa JC. New and emerging data from clinical trials of statins. Curr. Atheroscler. Rep. 6, 12–19 (2004).
   PubMedGoogle Scholar
• Koren MJ, Hunninhake DB, on behalf of the of the ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE Study. J. Am. Coll. Cardiol. 44, 1772–1779 (2004).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG et al., for the Reversing Atherosclerosis and Aggressive Lipid Lowering (REVERSAL) Investigators. Effect of intensive compared with moderate lipid lowering-therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291, 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 292, 1307–1316 (2004).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Færgeman O, Holme I, Olsson AG, Tikkanen MJ. Effect of greater LDL-C reductions on prognosis: The Incremental Decrease in End points through Aggressive Lipid Lowering (IDEAL) trial. Atherosclerosis 144(Suppl. 1), 38 (1998).
   Google Scholar
• MacMahon M, Kirkpatrick C, Cummings CE et al. A pilot study with simvastatin and folic acid/vitamin B12 in preparation for the Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH). Nutr. Metab. Cardiovasc. Dis. 10, 195–203 (2000).
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis 171, 145–155 (2003).
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R, for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361, 2005–2016 (2003).
   PubMed Web of Science ®Google Scholar
• Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:23). Br. Med. J. 316, 823–828 (1998).
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al., on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetics in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685–696 (2004).
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olsson AG, Ezekowitz MD et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285, 1711–1718 (2001).
   PubMed Web of Science ®Google Scholar
• Brown WV. Cholesterol lowering in atherosclerosis. Am. J. Cardiol. 86, 29–32h (2000).
   Google Scholar
• Gagné C, Bays HE, Weiss SR et al., for the Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol. 90, 1084–1091 (2001).
   Google Scholar
• Davidson MH, McGarry T, Bettis R et al., on behalf of the Ezetimibe Study Group. Ezetimibe coadministration with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. 40, 2125–2134 (2002).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al., for the Ezetimibe Study Group. Effect of ezetimibe coadministration with atorvastatin in 628 patients with primary hypercholesterolemia; a prospective, randomized, double-blind trial. Circulation 107, 2409–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Ito MK. Niacin-based therapy for dyslipidemia: past evidence and future advances. Am. J. Manag. Care 8(Suppl.), 315–322 (2002).
   PubMed Web of Science ®Google Scholar
• Pieper JA. Understanding niacin formulations. Am. J. Manag. Care 8(Suppl.), 308–314 (2002).
   PubMed Web of Science ®Google Scholar
• Knopp RH, Alagona P, Davidson M et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 47, 1097–1104 (1998).
   PubMed Web of Science ®Google Scholar
• Brown BG, Xhao XQ, Chait A et al. Simvastatin and niacin, anti-oxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med. 345, 1583–1592 (2001).
   PubMed Web of Science ®Google Scholar
• Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of once-daily niacin/lovastatin formulation in patients with dyslipidemia. Am. J. Cardiol. 89, 672–678 (2002).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med. 341, 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• Skrepnek GH. Cost–effectiveness analyses. In: Principles of Pharmacoeconomics. Bootman JL, Townsend RJ, McGhan WF (Eds), W Harvey Whitney Books Company, OH, USA 83–116 (2005).
   Google Scholar
• Morrison A, Glassberg H. Determinants of the cost-effectiveness of statins. J. Manag. Care Pharm. 9, 544–551 (2003).
   PubMedGoogle Scholar
• Eicher HG, Kong SX, Gerth WC, Mavros P, Jönsson B. Use of cost–effectiveness analysis in healthcare resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 7, 518–528 (2004).
   PubMedGoogle Scholar
• Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can. Med. Assoc. J. 146, 473–481 (1992).
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Improving health outcomes without increasing costs: maximizing the full potential of lipid reduction therapy in the primary and secondary prevention of coronary heart disease. Curr. Opin. Lipidol. 8, 366–374 (1997).
   Google Scholar
• Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost–effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA 265, 1145–1151 (1991).
   PubMed Web of Science ®Google Scholar
• Lowering blood cholesterol to prevent heart disease: Consensus Conference. JAMA 253, 2080–2086 (1985).
   PubMed Web of Science ®Google Scholar
• Grover SA, Coupal L, Paquet S, Zowall H. Cost–effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch. Intern. Med. 159, 593–600 (1999).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Kjekshus J, Berg K et al. Cholesterol lowering and the use of healthcare resources. Results from the Scandinavian Simvastatin Survival Study. Circulation 93, 1796–1802 (1996).
   PubMed Web of Science ®Google Scholar
• Ashraf T, Hay J, Pitt B et al. Cost–effectiveness of pravastatin in secondary prevention of coronary heart disease. Am. J. Cardiol. 78, 409–414 (1996).
   PubMedGoogle Scholar
• Johannesson M, Jonsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost–effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. N. Engl J. Med. 336, 332–336 (1997).
   PubMed Web of Science ®Google Scholar
• Ganz DA, Kuntz KM, Jacobson GA, Avorn J. Cost–effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann. Intern. Med. 132, 780–787 (2000).
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. Cost–effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals. Lancet 1–7 (2005).
   Google Scholar
• Jonsson B, Cook JR, Pedersen TR. The cost-effectiveness of lipid lowering in patients with diabetes: results from the 4S trial. Diabetologia 42, 1293–1301 (1999).
   PubMedGoogle Scholar
• Caro J, Klittich W, McGuire A et al. The West of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin. Br. Med. J. 315, 1577–1582 (1997).
   PubMedGoogle Scholar
• Hay JW, Wittels EH, Gotto AM. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am. J. Cardiol. 67, 789–796 (1991).
   PubMed Web of Science ®Google Scholar
• Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. JAMA 273, 1032–1038 (1995).
   PubMedGoogle Scholar
• Grover SA, Abrahamowicz M, Joseph L et al. The benefits of treating hyperlipidemia to prevent coronary heart disease: estimating changes in life expectancy and morbidity. JAMA 267, 816–822 (1992).
   PubMedGoogle Scholar
• Johannesson M, Borgquist L, Jonsson B et al. The cost-effectiveness of lipid lowering in Swedish primary healthcare. J. Intern. Med. 240, 23–29 (1996).
   PubMedGoogle Scholar
• Herman WH, Alexander CM, Cook JR et al. Effect of simvastatin treatment on cardiovascular resource utilization in impaired fasting glucose and diabetes: findings from the Scandinavian Simvastatin Survival Study. Diabetes Care 22, 1771–1778 (1999).
   PubMedGoogle Scholar
• Grover SA, Coupal L, Zowall H et al. How cost–effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 24, 45–50 (2001).
   PubMed Web of Science ®Google Scholar
• Grover SA, Coupal L, Zowall H, Dorais M. Cost–effectiveness of treating hyperlipidemia in the presence of diabetes: who should be treated? Circulation 102, 722–727 (2000).
   PubMed Web of Science ®Google Scholar
• Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH. Cost–effectiveness of statin therapy for the primary prevention of major coronary events in individuals with Type 2 diabetes. Diabetes Care 26, 1796–1801 (2003).
   PubMed Web of Science ®Google Scholar
• Schulman KA, Kinosian B, Jacobson TA et al. Reducing high blood cholesterol levels with drugs: cost-effectiveness of pharmacologic management. JAMA 264, 3025–3033 (1990).
   PubMed Web of Science ®Google Scholar
• Huse DM, Russell MW, Miller JD et al. Cost-effectiveness of statins. Am. J. Cardiol. 82, 1357–1363 (1998).
   PubMed Web of Science ®Google Scholar
• Koren MJ, Smith DG, Hunninghake DB et al. The cost of reaching national cholesterol education program (NCEP) goals in hypercholesterolaemic patients. Pharmacoeconomics 14, 59–70 (1998).
   PubMedGoogle Scholar
• Elliot WJ, Weir DR. Comparative cost–effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction. Am. J. Health Syst. Pharm. 56, 1726–1732 (1999).
   PubMedGoogle Scholar
• Hilleman DE, Phillips JO, Mohiuddin SM et al. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia. Clin. Ther. 21, 536–562 (1999).
   PubMedGoogle Scholar
• Russell MW, Huse DM, Miller JD, Kraemer DF, Hartz SC. Cost-effectiveness of HMG-CoA reductase inhibition in Canada. Can. J. Clin. Pharmacol. 8, 9–16 (2001).
   PubMedGoogle Scholar
• Hillman DE, Heineman SM, Foral PA. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: an analysis based on the CURVES study. Pharmacotherapy 20, 819–822 (2000).
   PubMedGoogle Scholar
• Chong PH, Varner D. Cost-efficacy analysis of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors based on results of the STELLAR trial: clinical implications for therapeutic selection. Pharmacotherapy 25, 270–278 (2005).
   PubMedGoogle Scholar
• Prosser LA, Stinnett AA, Goldman PA et al. Cost-effectiveness of cholesterol lowering therapies according to selected patients characteristics. Ann. Intern. Med. 132, 769–779 (2000).
   PubMed Web of Science ®Google Scholar
• Cook JR, Yin D, Alemao et al. Cost-effectiveness of ezetimibe coadministration in statin-treated patients not at cholesterol goal. Application to Germany, Spain, and Norway. Pharmacoeconomics 22(Suppl.), 49–61 (2004).
   PubMed Web of Science ®Google Scholar
• Armstrong EP, Zachry WM III, Malone DC. Cost-effectiveness of simvastatin and lovastatin/extended-release niacin to achieve LDL and HDL goal using NHANES data. J. Manag. Care Pharm. 10, 251–258 (2004).
   PubMedGoogle Scholar
• Hay JW. Evaluating the cost–effectiveness of statins [editorial]. J. Manag. Care Pharm. 10, 79–81 (2004).
   PubMedGoogle Scholar
• Marshall T. Coronary heart disease prevention: insights from modeling incremental cost-effectiveness. Br. Med. J. 327, 1264–1268 (2003).
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, on behalf of the European Consensus Panel on HDL-C. Raising high-density lipoprotein n cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel ion HDL-C. Curr. Med. Res. Opin. 20, 1253–1268 (2004).
   PubMed Web of Science ®Google Scholar
• Evans M, Roberts A, Davies S, Rees A. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments. Drugs 64, 1181–1196 (2004).
   PubMed Web of Science ®Google Scholar
• McGovern ME. Taking aim at HDL-C. Postgrad. Med. 17, 29–39 (2005).
   Google Scholar
• Navab M, Anantharamaiah GM, Reddy ST et al. Human apolipoprotein AI and AI-mimetic peptides: potential for Atherosclerosis reversal. Curr. Opin. Lipidol. 15, 645–649 (2004).
   Google Scholar
• Evans M, Robers A, Rees A. The future direction of cholesterol-lowering therapy. Curr. Opin. Lipidol. 13, 663–669 (2002).
   PubMed Web of Science ®Google Scholar
• Bays H, Stein EA. Pharmacotherapy for dyslipidemia: current therapies and future agents. Exp. Opin. Pharmacotherapy 4, 1901–1938 (2003).
   PubMed Web of Science ®Google Scholar